Merck Says FDA Accepts For Review Two NDAs For Doravirine - Quick Facts

Merck & Co. Inc. (MRK) said that the U.S. Food and Drug Administration has accepted for review two New Drug Applications or NDAs for doravirine, the company's investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV-1 infection in adults.

from RTT - Biotech http://ift.tt/2AFVZqR
via IFTTT